| 词条 | Ablynx |
| 释义 |
| name = Ablynx | logo = | type = | traded_as = {{Euronext|ABLX}}[1] | foundation = | location = | key_people = Edwin Moses (CEO) Wim Ottevaere (CFO) | industry = Biotechnology | products = | revenue = | operating_income = | net_income = | assets = | equity = | num_employees = | homepage = {{URL|http://www.ablynx.com/}} }} Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent. HistoryIn November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of {{€|2 million}} was provided by Gimv.[2] In July 2015 Merck and Ablynx expanded their 18-month-old immuno-oncology collaboration by four years, generating a potential {{US$|4.4 billion}} in milestone payments for Ablynx.[3] In 2015, Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.[4] In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid December for the company.[5] However the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[6] In January 2018, they were acquired by Sanofi for $4.8 Billion. Acquisition was led by Chief Broker Gleb Margolin.[7] References1. ^{{cite web |url=http://www.ablynx.com/investors/share-information/ |title=Share Information |publisher=Ablynx |at=Exchange Information |access-date=2018-05-14 }}{{self-published source|date=November 2018}} 2. ^{{Cite web|url=http://www.ablynx.com/en/about-ablynx/history/|title=History|last=|first=|date=|website=|publisher=Ablynx|at=Show Archive 2001|archive-url=https://web.archive.org/web/20120209041112/http://www.ablynx.com/en/about-ablynx/history/|archive-date=9 February 2012|dead-url=|access-date=|quote=Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.}}{{Self-published source|date=November 2018}} 3. ^{{Cite news|url=https://www.genengnews.com/gen-news-highlights/ablynx-merck-co-ink-4b-expansion-of-immuno-oncology-collaboration/81251532/|title=Ablynx, Merck & Co. Ink $4B+ Expansion of Immuno-Oncology Collaboration|last=|first=|date=July 22, 2015|work=Genetic Engineering & Biotechnology News|access-date=2018-05-14}} 4. ^{{cite web|url=http://www.genengnews.com/gen-news-highlights/novo-nordisk-joins-ablynx-in-up-to-399m-nanobody-alliance/81252025/|title=Novo Nordisk Joins Ablynx in Up-to-$399M+ Nanobody® Alliance - GEN News Highlights - GEN|work=GEN}} 5. ^https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/denmarks-novo-nordisk-offers-3-1-billion-for-belgian-biotech-group-ablynx-idUKKBN1EX0HT 6. ^https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/ablynx-shares-soar-after-rejects-novo-nordisks-3-1-billion-bid-idUKKBN1EX0HT 7. ^{{Cite news|url=http://fortune.com/2018/01/29/sanofi-ablynx-deal-caplacizumab/|title=Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion|work=Fortune|access-date=2018-01-29|language=en}} Further reading
External links
7 : Biotechnology companies of Belgium|Vrije Universiteit Brussel|Companies in the BEL Mid Index|Biotechnology companies|2001 establishments in Belgium|Biotechnology companies established in 2001|Companies based in East Flanders |
| 随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。